Articles from VETmAb Biosciences, Inc.

SAN DIEGO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- VETmAb Biosciences (VETmAb BIO), a clinical-stage biopharmaceutical company developing transformative biologics for pets, today announced positive clinical proof-of-concept results for VMB-C001a. VMB-C001a is a long-acting anti-IL-23 monoclonal antibody for canine chronic inflammatory enteropathy (CIE), often referred to as inflammatory bowel disease (IBD). VMB-C001a has been granted eligibility for the FDA-CVM’s expanded conditional approval (XCA) pathway.